BNB PLUS CORP. — fact timeline

BNB PLUS CORP. shareholders approved Election of six directors to serve until the 2024 annual meeting at the 2023-09-19 meeting.

“I. To elect six directors to serve until the 2024 annual meeting of stockholders or until their respective successors are duly elected and qualified. FOR WITHHELD BROKER NON- VOTES James A. Hayward 3,591,642 383,602 3,105,530 Robert B. Catell 3,572,859 402,385 3,105,530 Joseph D. Ceccoli 3,154,216 821,028 3,105,530 Yacov A. Shamash 3,005,706 969,538 3,105,530 Sanford R. Simon 3,514,258 460,986 3,105,530 Elizabeth Schmalz Shaheen 3,089,726 885,518 3,105,530”

BNB PLUS CORP. reported third quarter of fiscal 2023 ended June 30, 2023 results: revenue approximately $2.9 million, net income $3.1 million.

“potential for cotton taggant orders and the initiation of large supply chain customers.” Summary Third Quarter Fiscal 2023 Financial Results: · Total revenues were approximately $2.9 million for the three-month period June 30, 2023, compared to $4.3 million for the same period in the prior fiscal year. The decrease in revenue of approximately $1.4 million was due to”

Scott L. Anchin departed as Director at BNB PLUS CORP..

“On July 31, 2023, Scott L. Anchin, provided notice to Applied DNA Sciences, Inc. (the “Company”) of his intention not to stand for re-election as director at the Company’s upcoming annual meeting of stockholders”

BNB PLUS CORP. completed an acquisition involving Spindle Biotech Inc. for cash of $625,000 and 750,000 restricted shares of common stock, plus potential earn-out (closed 2023-07-12).

“the transactions contemplated by the Purchase Agreement, the Purchaser agreed to pay or issue to the Sellers, as applicable, on a pro rata basis: (i) a cash purchase price of $625,000, as adjusted for debt of Spindle as of the closing date and expenses related to the transaction, which was paid to the Sellers on the Closing Date; (ii) 750,000 restricted shares”

BNB PLUS CORP. entered into Share Purchase Agreement with Spindle Biotech Inc., the Sellers, and Lai Him Chung valued at $625,000 (effective 2023-07-12).

“On July 12, 2023 (the “Closing Date”), Spindle Acquisition Corp., a corporation existing under the laws of the Province of Ontario (the “Purchaser”), and a wholly-owned subsidiary of Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), entered into a Share Purchase Agreement (the “Purchase Agreement”) with Spindle Biotech Inc., a corporation existing under the federal laws of Canada (“Spindle”), the persons listed on Schedule 1.1 of the Purchase Agreement (the “Sellers”) and Lai Him Chung, as Seller Representative.”

BNB PLUS CORP. reported second quarter of fiscal 2023 ended March 31, 2023 results: revenue $4.4 million.

“Total revenues were $4.4 million for the three-month period ended March 31, 2023”

BNB PLUS CORP. entered into Amended and Restated Lease Agreement with Long Island High Technology Incubator, Inc. valued at Office Lease: base rent $48,861.17 per month from Feb 1, 2023 to Jan 31, 2024, then annual CPI adjus (effective 2023-02-24).

“On February 24, 2023, Applied DNA Sciences, Inc. (the “Company”) entered into that certain Amended and Restated Lease Agreement with Long Island High Technology Incubator, Inc. (the “Landlord”) with respect to the Company’s office space consisting of 30,000 gross rentable square feet in the building known as LIHTI 2 located at 50 Health Sciences Drive, Stony Brook, New York 11790 (the “Office Lease”). Also on February 24, 2023, the Company entered into that certain Amended and Restated Lease Agreement with the Landlord with respect to the Company’s laboratory space consisting of an aggregate of 2,500 gross rentable square feet located at 25 Health Sciences Drive, Stony Brook, New York 11790 (the “Laboratory Lease”).”

BNB PLUS CORP. reported first quarter of fiscal 2023, ended December 31, 2022 results: revenue $5.3 million.

“Applied DNA Reports First Quarter Fiscal 2023 Financial Results - Total Revenues of $5.3 Million”

BNB PLUS CORP. reported the fiscal year ended September 30, 2022 results: revenue $18.2 million.

“Total revenues increased 101% to $18.2 million, which included $15.5 million in clinical laboratory service revenues (COVID-19 test revenue).”

BNB PLUS CORP. reported the fourth quarter ended September 30, 2022 results: revenue $3.6 million.

“Total revenues increased 17% to $3.6 million, which included $2.9 million in clinical laboratory service revenues (COVID-19 testing revenue).”

John Bitzer, III departed as Director at BNB PLUS CORP..

“On July 28, 2022, John Bitzer, III, provided notice to the Board of Directors (the “Board”) of Applied DNA Sciences, Inc. (the “Company”) of his intention to retire from the Board and to not stand for re-election as director at the Company’s upcoming annual meeting of stockholders (the “Annual Meeting”), currently scheduled for September 22, 2022.”